Barinthus Biotherapeutics plc. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated statements of cash flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Share based compensation
Impairment of long-lived assets
Impairment of goodwill
Depreciation and amortization
ROU asset and liability
Change in fair value of derivatives embedded in convertible loan notes
Unrealized foreign exchange gain on convertible loan notes
Non-cash lease expenses
Unrealized foreign exchange loss
Change in contingent consideration
Non cash interest expense
Non-cash interest expense
Deferred tax benefit
Profit on sale of property and equipment
Changes in operating assets and liabilities:
Accounts receivable (including related parties)
Prepaid expenses and other current assets
Research and development incentives receivable
Accounts payable
Accrued expenses and other current liabilities
Deferred revenue
Deferred income
Operating lease liabilities
Other assets
Net cash used in operating activities

CASH FLOWS FROM INVESTING ACTIVITIES:
Acquisition of subsidiary, net of cash acquired
Proceeds from sale of property and equipment
Purchases of property and equipment
Net cash provided by/(used) in investing activities

CASH FLOWS FROM FINANCING ACTIVITIES:
Issue of shares and exercise of stock options
Issue of shares from the exercise of stock options
Contributions from noncontrolling interest
Proceeds from issue of ordinary shares, net of issuance costs
Payment of contingent consideration
Repayment of debt
Transaction costs for Series B shares
Proceeds from issue of Series B shares
Initial public offering cost
Proceeds from initial public offering
Net cash provided by financing activities

Effect of exchange rates on cash, cash equivalents and restricted cash
Net decrease in cash, cash equivalents and restricted cash
Cash, cash equivalents and restricted cash, beginning of the period
Cash, cash equivalents and restricted cash, end of the period
Cash paid for interest
Cash paid for income taxes
Issue of shares
Ordinary shares
Deferred A shares
Deferred B shares
Deferred C shares
Series B shares
Conversion of Series A and B to ordinary shares
Cash consideration on acquisition of subsidiary payable
Purchases of property and equipment included in accounts payable and accrued liabilities
ROU assets obtained in exchange for operating lease liabilities
Asset retirement obligation
Changes to right-of-use asset resulting from lease reassessment event
Measurement period adjustments
Contingent Consideration settled in equity

Comments